The View’s Joy Behar Is Furious TrumpRX Is Lowering Drug Costs

One day, historians may look back at The View and conclude the program functioned less as political commentary and more as accidental satire.

Read more Advice for Ken Paxton

That conclusion became even more plausible last week after co-host Joy Behar suggested Americans could effectively “die” because President Trump is attempting to lower prescription drug costs through the TrumpRX program.

Yes — lower drug prices are apparently now dangerous.

Yes — lower drug prices are apparently now dangerous.

The outrage followed the administration’s announcement last Monday that roughly 600 additional generic medications would be added to the TrumpRX initiative, expanding access to lower-cost purchasing options for millions of Americans. The administration estimates the broader effort could save consumers and seniors hundreds of billions of dollars over the next decade.

For years, Americans have heard celebrities, progressive activists, and Democratic politicians insist that high prescription drug costs represent one of the country’s great moral failures. Entire campaigns were built around the idea that seniors were rationing medicine while pharmaceutical costs spiraled out of control.

But now that a Republican administration is pursuing a more market-oriented strategy aimed at reducing prices without fully federalizing healthcare, many of those same voices suddenly sound horrified.

Apparently, lowering drug costs is only admirable when it arrives wrapped inside a massive government expansion program and signed by the “correct” political party.

To be fair, policymakers should approach any pharmaceutical pricing framework cautiously — whether proposed by Republicans or Democrats. Heavy-handed government intervention in drug pricing can produce serious long-term consequences, including reduced research investment, supply distortions, diminished innovation, and fewer breakthrough therapies over time.

Those concerns are real. They deserve serious discussion.

But that is precisely why the current reaction from much of the media and progressive political world is so revealing. TrumpRX, whatever its imperfections, is still clearly addressing affordability concerns through expanded generic access, pricing transparency, and efforts to reduce the influence of opaque intermediary structures that have distorted healthcare markets for years. (RELATED: What We Risk Losing in the Push for Cheaper Drugs)

That matters because much of the frustration consumers experience today does not stem solely from pharmaceutical innovation itself, but from the bloated architecture surrounding prescription drug distribution and reimbursement.

For decades, Americans have been trapped inside a labyrinth of pharmacy benefit managers, rebate systems, opaque pricing arrangements, formulary negotiations, and administrative middlemen that often leave patients paying artificially inflated prices while large institutional players profit handsomely behind the scenes. (RELATED: Why Americans Pay More for Healthcare and Still Can’t Afford It)

Reducing those distortions should not be controversial.

Yet on programs like The View, market-oriented healthcare reforms are frequently treated as morally suspect while centralized government control is portrayed as enlightened compassion.

When Bernie Sanders appeared on the program advocating government-run healthcare systems, the hosts responded with near enthusiasm. Missing from those conversations were many of the difficult realities that accompany heavily centralized healthcare systems around the world.

There was little discussion of lengthy specialist wait times in countries like Canada and the United Kingdom, where bureaucratic cost-management decisions routinely shape patient access to care. There was little discussion of rationing pressures, delayed treatments, or the tradeoffs that emerge when governments become the dominant purchasers and price-setters within healthcare systems.

Nor was there much discussion of the deeply troubling controversies surrounding medically assisted dying policies in Canada, including reports that vulnerable patients were at times steered toward euthanasia discussions amid broader system strains and resource pressures. (RELATED: Oh No, Canada!)

Those realities do not mean America should ignore affordability concerns. They do, however, illustrate why policymakers must be careful not to confuse healthcare reform with ever-expanding government control.

Innovation and affordability do not have to be enemies.

The United States continues to lead the world in pharmaceutical development because our system — despite its flaws — still rewards scientific risk-taking, capital investment, and medical innovation. Many of the world’s most important breakthrough therapies were developed precisely because companies had incentives to invest billions of dollars into uncertain research and development efforts. (RELATED: Why Your Phone Got Cheaper — and Your Health Insurance Didn’t)

At the same time, Americans are entirely justified in demanding greater transparency, lower out-of-pocket costs, and more competitive pricing structures.

The challenge is achieving those goals without replacing one distorted system with another.

That is where TrumpRX represents a meaningful shift in the right direction. Rather than relying exclusively on centralized price controls or sweeping government management of healthcare delivery, the initiative attempts to increase competition, expand generic access, improve price visibility, and weaken the grip of entrenched intermediary structures.

Is it perfect? Of course not.

Policymakers should remain vigilant to ensure that short-term political pressure to reduce prices does not gradually evolve into counterproductive government coercion that ultimately undermines pharmaceutical innovation and long-term patient access. Any administration — Republican or Democrat — can drift too far in that direction if affordability goals become disconnected from economic reality.

But treating lower drug costs as some kind of existential threat, as the hosts of The View effectively did this week, is both intellectually unserious and politically revealing.

Americans should not have to choose between affordable medicine and continued innovation. A disciplined, market-oriented healthcare system should be capable of supporting both.

That is the real debate policymakers should be having — not whether consumers deserve relief from inflated healthcare costs, but how to achieve that relief without sacrificing the innovation, flexibility, and long-term resilience that make modern medicine possible in the first place.

Andrew Langer is director of the Center for Regulatory Freedom at the CPAC Foundation.